UnknownNot Applicable

PROTEUS: Evaluating the Use of Artificial Intelligence to Support Stress Echocardiography Testing for Heart Disease

United Kingdom2,338 participantsStarted 2021-11-08

Plain-language summary

PROTEUS is a multicentre, two arm, randomised controlled trial of a medical device to assess the impact of the introduction of EchoGo into the standard care pathway for stress echocardiology.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Willing and able to provide informed consent * Male or female, ≥18 years of age at study entry * Referred to an NHS Trust for stress echocardiography for investigation of ischaemic heart disease Exclusion Criteria: * More than moderate valvular heart disease * Left ventricular outflow tract obstruction defined as a gradient \> 30mmHg (fixed or dynamic; supravalvular, valvular or sub-valvular) * Significant co-morbidities (e.g. cancer) with an expected life-expectancy of under 12 months in the investigator's opinion * Previous coronary artery bypass graft or other cardiac surgery * Congenital or inherited myocardial disease

What they're measuring

Investigate if EchoGo plus standard care is non-inferior to standard care alone for aiding referral to coronary angiogram following stress echocardiogram (SE)

Timeframe: 6 months post stress echo

Trial details

NCT IDNCT05028179

SponsorUltromics Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-06-30

View on ClinicalTrials.gov More Coronary Heart Disease trials